| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Expert Consensus |
| Article Title |
First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Maryam Alkhatry, Ahmad Al-Rifai, Vito Annese, Filippos Georgopoulos, Ahmad N Jazzar, Ahmed M Khassouan, Zaher Koutoubi, Rahul Nathwani, Mazen S Taha and Jimmy K Limdi |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Emirates Gastroenterology and Hepatology Society |
001802 |
|
| Corresponding Author |
Vito Annese, MD, PhD, Assistant Professor, Director, Director, Department of Gastroenterolog, Valiant Clinic, City Walk 13th Street, Dubai N/A, United Arab Emirates. vitoannese1@gmail.com |
| Key Words |
Ulcerative colitis; Crohn’s disease; Infliximab; Adalimumab; Vedolizumab; Ustekinumab |
| Core Tip |
Prevalence of ulcerative colitis and Crohn’s disease is on rise worldwide including Middle East. The progressive advance in our understanding of the etiopathogenesis coupled with an unprecedented increase in therapeutic options have progressive changed the management towards to a tailoring evidence-based intervention. In the consensus, statements have been agreed about the diagnosis of inflammatory bowel diseases based on the clinical evaluation and a combination of endoscopic, histological, radiological, and/or biochemical findings. In addition, the therapeutic options including biological and “small molecule” therapies have been revised in view of the treatment goals, which now aim to treat beyond “symptoms”, to achieve mucosal healing when possible and to minimise intestinal injury and bowel damage with resultant disability. |
| Publish Date |
2020-11-20 04:04 |
| Citation |
Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i43/6710.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i43.6710 |
